Close Menu

cancer of unknown primary

The company said it plans to publish its findings on its early-detection cancer tests, and will work with CMS and the FDA on pre-market review. 

Empire said it expects to generate $5 million or more in revenues from the Chinese market over the five-year term of the agreement with HemaTone.

COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.

The company also said it has signed a collaboration deal with Bristol-Myers Squibb to evaluate the efficacy of immuno-oncology molecular profiling.

The prize was established in 2013 to help fund explorative and high-risk/high-reward cancer research in areas where traditional funding is often lacking.

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.

N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.

The state of California has given the lab permission to start offering its QClamp test to screen for tumor oncogenic driver and resistance mutations in tumor DNA.

The partners will investigate whether RareCyte's technology can be used to analyze immune cell populations and CTCs in samples from NCI studies.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.